Radiopharmaceutical production system, radiopharmaceutical production device, and production method for radiopharmaceuticals

Patent metadata

Field	Value
Publication number	US-2017323696-A1
Application number	US-201515520266-A
Country	US
Kind code	A1
Filing date	Oct 14, 2015
Priority date	Oct 20, 2014
Publication date	Nov 9, 2017
Grant date	—

Abstract

The present invention comprises: an electron beam accelerator ( 2 ); a container ( 4 ) housing a raw material ( 3 ) for radioactive nuclide production, said raw material including molybdenum 100; a heating device ( 5 ) that heats the raw material ( 3 ) for radioactive nuclide production; an adsorbent ( 81 ) that adsorbs technetium compounds including technetium 99m generated by the heated raw material ( 3 ) for radioactive nuclide production; an eluent supply device ( 10 ) that supplies an eluent (L 1 ) that causes elution of the technetium compound adsorbed to the adsorbent ( 81 ); and a drug recovery unit ( 13 ) that recovers the eluent (L 2 ).

First claim

1 . A radiopharmaceutical production system comprising:
a radionuclide production device that produces molybdenum 99 by nuclear reaction through irradiation of a molybdenum 100-containing radionuclide feedstock with radiation generated by using electrons accelerated with an electron beam accelerator; and a radiopharmaceutical production device that heats the radionuclide feedstock to evaporate a technetium compound containing technetium 99m generated by radioactive decay of molybdenum 99, and adsorbs the evaporated technetium 99m-containing technetium compound to an adsorbent, and in which an eluent is passed through the adsorbent adsorbing the technetium 99m-containing technetium compound, and the technetium 99m-containing technetium compound is eluted into the eluent to produce a radiopharmaceutical.

2 . The radiopharmaceutical production system according to claim 1 , wherein the molybdenum 100-containing radionuclide feedstock is a molybdenum metal or molybdenum trioxide.

3 . The radiopharmaceutical production system according to claim 1 , wherein the technetium 99m-containing technetium compound is evaporated under a stream of gas.

4 . The radiopharmaceutical production system according to claim 3 , wherein the gas is oxygen gas, or a mixed gas of oxygen gas and inert gas.

5 . The radiopharmaceutical production system according to claim 1 , wherein a saline is passed as the eluent through the adsorbent adsorbing the technetium 99m-containing technetium compound to produce a saline solution of technetium 99m, and the solution is added to a drug for radiopharmaceutical production.

6 . The radiopharmaceutical production system according to claim 1 , wherein the adsorbent supports a drug for radiopharmaceutical production, and the eluent is passed through the adsorbent adsorbing the technetium 99m-containing technetium compound to synthesize the radiopharmaceutical.

7 . The radiopharmaceutical production system according to claim 1 , wherein the eluent is a saline containing a drug for radiopharmaceutical production, and the eluent is passed through the adsorbent adsorbing the technetium 99m-containing technetium compound to synthesize the radiopharmaceutical.

8 . The radiopharmaceutical production system according to claim 1 , wherein the radionuclide feedstock is heated at a temperature that does not evaporate the molybdenum compound but selectively evaporates the technetium compound.

9 . The radiopharmaceutical production system according to claim 8 , wherein the adsorbent contains any one of fibrous quartz, alumina, silica gel, an organic material fiber, activated carbon, and an ion-exchange resin.

10 . The radiopharmaceutical production system according to claim 1 , wherein the radionuclide feedstock is heated at a temperature that evaporates the molybdenum compound and the technetium compound.

11 . The radiopharmaceutical production system according to claim 10 , wherein adsorbent selectively adsorbs the technetium compound from a mixture of the molybdenum compound and the technetium compound.

12 . The radiopharmaceutical production system according to claim 8 , wherein the molybdenum compound and the technetium compound are oxides.

13 . The radiopharmaceutical production system according to claim 10 , further comprising:
a feedstock collector that collects the molybdenum compound from an offgas that passed through the adsorbent; and a feedstock re-feeder that enables the collected molybdenum compound to be reused as the radionuclide feedstock.

14 . A radiopharmaceutical production device comprising:
an electron beam accelerator; a container for housing a molybdenum 100-containing radionuclide feedstock to be irradiated with radiation generated by using electrons accelerated with the electron beam accelerator; a heater for heating the radionuclide feedstock housed in the container; an adsorbent that adsorbs a technetium compound, the technetium compound contains technetium 99m, the technetium compound is generated upon heating the radionuclide feedstock irradiated with the radiation; an eluent feeder that supplies an eluent for eluting from the adsorbent the technetium 99m-containing technetium compound adsorbed to the adsorbent; and a drug collecting section that collects the eluent.

15 . A method for producing a radiopharmaceutical,
the method comprising: producing molybdenum 99 by nuclear reaction through irradiation of a molybdenum 100-containing radionuclide feedstock with radiation generated by using electrons accelerated with an electron beam accelerator; heating the radionuclide feedstock to evaporate a technetium compound containing technetium 99m produced by radioactive decay of molybdenum 99; adsorbing the evaporated technetium 99m-containing technetium compound to an adsorbent; and passing an eluent through the adsorbent adsorbing the technetium 99m-containing technetium compound, and eluting the technetium 99m-containing technetium compound into the eluent to produce a radiopharmaceutical.

Assignees

• Hitachi Ltd

Inventors

• KANI Yuuko
• Tadokoro Takahiro

Classifications

• G21G1/10

  by bombardment with electrically charged particles (irradiation devices G21K5/00) · CPC title

• A61K51/025

  inorganic Tc complexes or compounds · CPC title

• G21G4/08 Primary

  specially adapted for medical application (radiation therapy using radioactive sources A61N5/10) · CPC title

• G21G1/12

  by electromagnetic irradiation, e.g. with gamma or X-rays (applications of radiation G21H5/00; irradiation devices G21K5/00) · CPC title